MARKET

TECX

TECX

Tectonic Therapeutic Inc
NASDAQ
30.76
+0.17
+0.56%
Opening 15:46 06/24 EDT
OPEN
30.59
PREV CLOSE
30.59
HIGH
31.61
LOW
30.59
VOLUME
56.41K
TURNOVER
--
52 WEEK HIGH
36.03
52 WEEK LOW
14.39
MARKET CAP
580.42M
P/E (TTM)
-6.8989
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TECX last week (0615-0619)?
Weekly Report · 2d ago
Weekly Report: what happened at TECX last week (0608-0612)?
Weekly Report · 06/15 09:57
Analysts Offer Insights on Healthcare Companies: Amneal Pharmaceuticals (AMRX), Elevance Health (ELV) and Tectonic Therapeutic (TECX)
TipRanks · 06/11 09:21
Tectonic Completes Enrollment In Phase 2 APEX Trial For TX-45 In Pulmonary Hypertension Subtype
NASDAQ · 06/11 06:24
Analysts Are Bullish on Top Healthcare Stocks: Humacyte (HUMA), Tectonic Therapeutic (TECX)
TipRanks · 06/10 23:10
Tectonic Therapeutic Completes Enrollment in Key TX45 Trial
TipRanks · 06/10 22:31
Analysts Offer Insights on Healthcare Companies: Tectonic Therapeutic (TECX) and Stevanato Group (STVN)
TipRanks · 06/10 21:20
Tectonic Therapeutic files Form 3 for director Jessica Caroline Chutter
PUBT · 06/10 20:35
More
About TECX
Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Its product candidates are TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. Its second development candidate, TX2100, is a VHH-Fc fusion antagonist antibody that binds to the APJ receptor (APLNR), also known as the apelin receptor. Its APJ is a differentiated approach for the treatment of hereditary hemorrhagic telangiectasia (HHT) and is a selective anti-angiogenic target that is primarily expressed in endothelial cells.

Webull offers Tectonic Therapeutic Inc stock information, including NASDAQ: TECX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TECX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TECX stock methods without spending real money on the virtual paper trading platform.